Aprotinin decreases ischemic damage during coronary revascularization

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Research

Background:

• Ischemic heart disease remains a leading cause of mortality.
• Reperfusion injury after myocardial revascularization can exacerbate tissue damage.
• Aprotinin, an anti-inflammatory agent, has shown potential in mitigating such injuries.

Purpose of the Study:

• To investigate the efficacy of aprotinin in limiting myocardial ischemic damage during revascularization.
• To assess the anti-inflammatory effects of aprotinin in the context of acute coronary occlusion and reperfusion.

Main Methods:

• A porcine model of myocardial ischemia-reperfusion was utilized (90 min occlusion, 45 min cardioplegic arrest, 180 min reperfusion).
• Animals received either aprotinin (loading dose + infusion) or no treatment.
• Key outcome measures included ventricular arrhythmias, lung water accumulation, coronary response to bradykinin, and infarct size.

Main Results:

• Aprotinin treatment led to significantly fewer cardioversions for ventricular arrhythmias (p < 0.001).
• Animals treated with aprotinin exhibited reduced lung water accumulation (p = 0.038) and improved coronary relaxation (p = 0.01).
• Aprotinin significantly decreased infarct size (p = 0.003).

Conclusions:

• Aprotinin effectively limits ischemic injury during acute coronary revascularization.
• The protective effects include reduction in ventricular arrhythmias and lung edema.
• Aprotinin preserves endothelial function and minimizes myocardial necrosis, highlighting its therapeutic potential.